PET Chemistry The Driving Force in Molecular Imaging /

Personalized medicine employing patient-based tailor-made therapeutic drugs is taking over treatment paradigms in a variety of ?elds in oncology and the central nervous system. The success of such therapies is mainly dependent on ef?cacious therapeutic drugs and a selective imaging probe for identi?...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Schubiger, P. A. (Επιμελητής έκδοσης), Lehmann, L. (Επιμελητής έκδοσης), Friebe, M. (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Berlin, Heidelberg : Springer Berlin Heidelberg, 2007.
Σειρά:Ernst Schering Research Foundation Workshop, 64
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04481nam a22005775i 4500
001 978-3-540-49527-7
003 DE-He213
005 20151204170039.0
007 cr nn 008mamaa
008 100301s2007 gw | s |||| 0|eng d
020 |a 9783540495277  |9 978-3-540-49527-7 
024 7 |a 10.1007/978-3-540-49527-7  |2 doi 
040 |d GrThAP 
050 4 |a QD1-999 
072 7 |a PN  |2 bicssc 
072 7 |a SCI013000  |2 bisacsh 
072 7 |a TEC012000  |2 bisacsh 
082 0 4 |a 540  |2 23 
245 1 0 |a PET Chemistry  |h [electronic resource] :  |b The Driving Force in Molecular Imaging /  |c edited by P. A. Schubiger, L. Lehmann, M. Friebe. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg,  |c 2007. 
300 |a XII, 345 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Ernst Schering Research Foundation Workshop,  |x 0947-6075 ;  |v 64 
505 0 |a Molecular Imaging with PET — Open Questions? -- Fluorine-18 Labeling Methods: Features and Possibilities of Basic Reactions -- Fluorine-18 Labeling of Small Molecules: The Use of 18F-Labeled Aryl Fluorides Derived from No-Carrier-Added [18F]Fluoride as Labeling Precursors -- Fluorine-18 Labeling of Peptides and Proteins -- [18F]Fluoropyridines: From Conventional Radiotracers to the Labeling of Macromolecules Such as Proteins and Oligonucleotides -- Production of Non-standard PET Radionuclides and the Application of Radiopharmaceuticals Labeled with these Nuclides -- Carbon-11 Labeling Chemistry Based upon [11C]Methyl Iodide -- 68Ga-PET Radiopharmacy: A Generator-Based Alternative to 18F-Radiopharmacy -- Microwaving in F-18 Chemistry: Quirks and Tweaks -- Micro-reactors for PET Tracer Labeling -- Synthesis Modules and Automation in F-18 Labeling -- Pharmacological Prerequisites for PET Ligands and Practical Issues in Preclinical PET Research -- Positron Emission Tomography Imaging as a Key Enabling Technology in Drug Development. 
520 |a Personalized medicine employing patient-based tailor-made therapeutic drugs is taking over treatment paradigms in a variety of ?elds in oncology and the central nervous system. The success of such therapies is mainly dependent on ef?cacious therapeutic drugs and a selective imaging probe for identi?cation of potential responders as well as therapy monitoring for an early bene?t assessment. Molecular imaging (MI) is based on the selective and speci?c interaction of a molecular probe with a biological target which is visualized through nuclear, magnetic resonance, near infrared or other methods. Therefore it is the method of choice for patient selection and therapy monitoring as well as for speci?c e- point monitoring in modern drug development. PET (positron emitting tomography), a nuclear medical imaging modality, is ideally suited to produce three-dimensional images of various targets or processes. The rapidly increasing demand for highly selective probes for MI strongly pushes the development of new PET tracers and PET chemistry. ‘PET chemistry’ can be de?ned as the study of positron-emitting compounds regarding their synthesis, structure, composition, reactivity, nuclear properties and processes and their properties in natural and - natural environments. In practice PET chemistry is strongly in?uenced by the unique properties of the radioisotopes used (e. g. , half-life, che- cal reactivity, etc. ) and integrates scienti?c aspects of nuclear-, organic-, inorganic- and biochemistry. 
650 0 |a Chemistry. 
650 0 |a Inorganic chemistry. 
650 0 |a Organic chemistry. 
650 0 |a Bioorganic chemistry. 
650 0 |a Nuclear chemistry. 
650 0 |a Nuclear medicine. 
650 1 4 |a Chemistry. 
650 2 4 |a Chemistry/Food Science, general. 
650 2 4 |a Nuclear Medicine. 
650 2 4 |a Nuclear Chemistry. 
650 2 4 |a Organic Chemistry. 
650 2 4 |a Inorganic Chemistry. 
650 2 4 |a Bioorganic Chemistry. 
700 1 |a Schubiger, P. A.  |e editor. 
700 1 |a Lehmann, L.  |e editor. 
700 1 |a Friebe, M.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783540326236 
830 0 |a Ernst Schering Research Foundation Workshop,  |x 0947-6075 ;  |v 64 
856 4 0 |u http://dx.doi.org/10.1007/978-3-540-49527-7  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)